Enrollment is complete in the Phase 2b VISTAS clinical trial, which is testing the experimental oral treatment volixibat in people with itching due to primary sclerosing cholangitis (PSC). Top-line results from VISTAS (NCT04663308), whose recruitment reached 182 participants, are expected between April and June of next year. “Completing enrollment in VISTAS is a major milestone […] The post Phase 2 trial of volixibat for PSC-related itching now fully enrolled appeared first on Liver Disea...| Liver Disease News – The Web's Daily Resource for Liver Disease News